Videos

Chad Pettit, executive director of marketing and team leader for global biosimilar launches at Amgen, discusses the potential for a level playing field for biosimilars and reference products.

Chad Pettit, MBA, executive director of marketing and team leader for global biosimilar launches at Amgen, discussed Amgen’s recent report on the state of the US biosimilars marketplace.

Here are the top 5 biosimilar articles for the week of October 19, 2020.

Edward Li, PharmD, director of Health Economics and Outcomes Research for Sandoz, discussed how biosimilar filgrastim (Zarxio) used as primary prophylaxis saves money and helps reduce the risk of febrile neutropenia in patients with cancer.

Here are the top 5 biosimilar articles for the week of October 12, 2020.

Thomas Wakim, strategic analyst for Neuclone, discussed the company’s decision to break into the world of PD-1 inhibitors, its partnership with the Serum Institute in India, and Neuclone’s biosimilar pipeline.

Here are the top 5 biosimilar articles for the week of October 5, 2020.

Ryan Cox, vice president of the Access Experience Team at PRECISIONvalue, discusses whether midsize employers can participate in payer discussions on formulary placement.

Ryan Cox, vice president of the Access Experience Team at PRECISIONvalue, discusses what employers can do to encourage biosimilar uptake and what cultural changes are needed to make it happen.

Sean McGowan, senior director of biosimilars at AmerisouceBergen, discussed the current biosimilar pipeline and the potential impact on the market those products may have.

Here are the top 5 biosimilar articles for the week of September 28, 2020.

Sean McGowan, senior director of Biosimilars at AmerisourceBergen, discusses the physician and practice issues with having multiple biosimilars for the same molecule on the market and what is needed to ensure more biosimilar competition in the future.

Sean McGowan, senior director of Biosimilars at AmerisourceBergen, discussed the challenges of bringing a new biosimilar to market both generally and during the time of the coronavirus disease 2019 (COVID-19) pandemic.

Here are the top 5 biosimilar articles for the week of September 21, 2020.

Hillel Cohen, PhD, Education Committee co-chair for the Biosimilars Forum and executive director of Scientific Affairs for Sandoz, discussed whether disclosure statements are needed for biosimilar products and what they should contain, according to the biosimilar industry perspective.

Here are the top 5 biosimilar articles for the week of September 14, 2020.

Wayne Winegarden, PhD, senior fellow in business and economics at the Pacific Research Institute (PRI) and director of PRI’s Center for Medical Economics and Innovation, discussed why importing drugs may not lower costs and what we can learn from Canada’s biosimilar programs.

Wayne Winegarden, PhD, senior fellow in business and economics at the Pacific Research Institute (PRI) and director of PRI’s Center for Medical Economics and Innovation, discussed where the biosimilar market is heading and how employers can incentivize biosimilar utilization.

Here are the top 5 biosimilar articles for the week of September 7, 2020.

Brian Gifford, research director of the Integrated Benefits Institute (IBI), discussed how employers can improve treatment adherence for their employees with rheumatic conditions in order to keep them productive and on the job.

Brian Gifford, research director of the Integrated Benefits Institute (IBI), discussed employer challenges with managing expenses associated with rheumatoid arthritis and how skillful management of rheumatoid arthritis can keep employees on the job and reduce expense.

Here are the top 5 biosimilar articles for the week of August 31, 2020.

Surya Singh, MD, president and owner of Singh Healthcare Advisors LLC in Lexington, Massachusetts, discussed the future for the US adalimumab market and whether biosimilars can deliver on the promise of lower cost health care.

Surya Singh, MD, president and owner of Singh Healthcare Advisors LLC in Lexington, Massachusetts, discussed how payers’ decisions regarding formulary lists affect patient out-of-pocket costs and access to biosimilars.

Here are the top 5 biosimilar articles for the week of August 24, 2020.

Cheryl Larson, president and CEO of the Midwest Business Group on Health, based in Chicago, Illinois, discussed what employers can do to get biosimilars added to their formulary lists and ensure their pharmacy benefit managers (PBMs) aren’t taking advantage of them.

Cheryl Larson, president and CEO of Midwest Business Group on Health, based in Chicago, Illinois, discussed how some employers are taking on pharmacy benefit managers (PBMs) to get biosimilars added to their formularies and what it could mean for biosimilar savings going forward.

Here are the top 5 biosimilar articles for the week of August 17, 2020.

Swaminathan P. Iyer, MD, a professor of medicine in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discussed oncology biologics that are too costly for patients whether the Doha Declaration, which would enable governments to license the manufacture of these products, is a viable option.

Swaminathan Iyer, MD, a professor of medicine in the Department of Lymphoma and Myeloma at the University of Texas MD Anderson Cancer Center, discussed the importance of biosimilars in India and the United States and the main concerns originator companies have regarding biosimilar competition.